Literature DB >> 31332074

Activation of 6-Alkoxy-Substituted Methylenecyclopropane Nucleoside Analogs Requires Enzymatic Modification by Adenosine Deaminase-Like Protein 1.

Kathryn J Vollmer1, Anna C Burns1, Hannah E Sauer1, John D Williams2, Gloria Komazin-Meredith2, Steve Cardinale2, Michelle Butler2, Zachary Aron2, Islam Hussein2, Marc G Busch3, Terry L Bowlin2, Brian G Gentry4.   

Abstract

To determine the mechanism of action of third-generation methylenecyclopropane nucleoside analogs (MCPNAs), DNA sequencing of herpes simplex virus 1 (HSV-1) isolates resistant to third-generation MCPNAs resulted in the discovery of G841S and N815S mutations in HSV-1 UL30. Purified HSV-1 UL30 or human cytomegalovirus (HCMV) UL54 was then subjected to increasing concentrations of MBX-2168-triphosphate (TP), with results demonstrating a 50% inhibitory concentration (IC50) of ∼200 μM, indicating that MBX-2168-TP does not inhibit the viral DNA polymerase. Further metabolic studies showed the removal of a moiety on the guanine ring of MBX-2168. Therefore, we hypothesized that enzymatic removal of a moiety at the 6-position of the guanine ring of third-generation MCPNAs is an essential step in activation. To test this hypothesis, pentostatin (deoxycoformycin [dCF]), an adenosine deaminase-like protein 1 (ADAL-1) inhibitor, was coincubated with MBX-2168. The results showed that dCF antagonized the effect of MBX-2168, with a >40-fold increase in the 50% effective concentration (EC50) at 50 μM dCF (EC50 of 63.1 ± 8.7 μM), compared with MBX-2168 alone (EC50 of 0.2 ± 0.1 μM). Purified ADAL-1 demonstrated time-dependent removal of the moiety on the guanine ring of MBX-2168-monophosphate (MP), with a Km of 17.5 ± 2.4 μM and a V max of 0.12 ± 0.04 nmol min-1 Finally, synguanol-TP demonstrated concentration-dependent inhibition of HSV-1 UL30 and HCMV UL54, with IC50s of 0.33 ± 0.16 and 0.38 ± 0.11 μM, respectively. We conclude that ADAL-1 is the enzyme responsible for removing the moiety from the guanine ring of MBX-2168-MP prior to conversion to a TP, the active compound that inhibits the viral DNA polymerase.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  antiviral; herpes simplex virus; human cytomegalovirus; viral DNA polymerase

Year:  2019        PMID: 31332074      PMCID: PMC6761536          DOI: 10.1128/AAC.01301-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

1.  In vitro activity and mechanism of action of methylenecyclopropane analogs of nucleosides against herpesvirus replication.

Authors:  Earl R Kern; Nicole L Kushner; Caroll B Hartline; Stephanie L Williams-Aziz; Emma A Harden; Shaoman Zhou; Jiri Zemlicka; Mark N Prichard
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

Review 2.  Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance.

Authors:  J B Houston
Journal:  Biochem Pharmacol       Date:  1994-04-29       Impact factor: 5.858

Review 3.  Antiviral drugs for cytomegalovirus diseases.

Authors:  Karen K Biron
Journal:  Antiviral Res       Date:  2006-05-23       Impact factor: 5.970

4.  Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy.

Authors:  F L Moolten
Journal:  Cancer Res       Date:  1986-10       Impact factor: 12.701

5.  (Z)- and (E)-2-((hydroxymethyl)cyclopropylidene)methyladenine and -guanine. New nucleoside analogues with a broad-spectrum antiviral activity.

Authors:  Y L Qiu; M B Ksebati; R G Ptak; B Y Fan; J M Breitenbach; J S Lin; Y C Cheng; E R Kern; J C Drach; J Zemlicka
Journal:  J Med Chem       Date:  1998-01-01       Impact factor: 7.446

6.  Metabolism of cyclopropavir and ganciclovir in human cytomegalovirus-infected cells.

Authors:  Brian G Gentry; John C Drach
Journal:  Antimicrob Agents Chemother       Date:  2014-02-10       Impact factor: 5.191

7.  Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions.

Authors:  Gloria Komazin-Meredith; Sunwen Chou; Mark N Prichard; Caroll B Hartline; Steven C Cardinale; Katelyn Comeau; John D Williams; Atiyya R Khan; Norton P Peet; Terry L Bowlin
Journal:  Antimicrob Agents Chemother       Date:  2013-10-21       Impact factor: 5.191

8.  Kaposi Sarcoma Pathogenesis: A Triad of Viral Infection, Oncogenesis and Chronic Inflammation.

Authors:  Janet L Douglas; Jean K Gustin; Ashlee V Moses; Bruce J Dezube; Liron Pantanowitz
Journal:  Transl Biomed       Date:  2010

Review 9.  Antiviral drugs for viruses other than human immunodeficiency virus.

Authors:  Raymund R Razonable
Journal:  Mayo Clin Proc       Date:  2011-10       Impact factor: 7.616

Review 10.  Clinical Features of Varicella-Zoster Virus Infection.

Authors:  Peter G E Kennedy; Anne A Gershon
Journal:  Viruses       Date:  2018-11-02       Impact factor: 5.048

View more
  1 in total

1.  Pentostatin antagonizes the antiviral activity of MBX-2168 by inhibiting the biosynthesis of the active compound.

Authors:  Natalie R Hagen; Marie L Nguyen; John D Williams; Terry L Bowlin; Brian G Gentry
Journal:  Antiviral Res       Date:  2021-01-18       Impact factor: 5.970

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.